Selling, General, and Administrative Costs: ACADIA Pharmaceuticals Inc. vs Iovance Biotherapeutics, Inc.

Biotech SG&A Expenses: ACADIA vs. Iovance

__timestampACADIA Pharmaceuticals Inc.Iovance Biotherapeutics, Inc.
Wednesday, January 1, 2014327480009335772
Thursday, January 1, 20159080400012390000
Friday, January 1, 201618645600025602000
Sunday, January 1, 201725506200021262000
Monday, January 1, 201826575800028430000
Tuesday, January 1, 201932563800040849000
Wednesday, January 1, 202038866100060210000
Friday, January 1, 202139602800083664000
Saturday, January 1, 2022369090000104097000
Sunday, January 1, 2023402466000106916000
Loading chart...

Data in motion

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of ACADIA Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc. from 2014 to 2023. Over this period, ACADIA consistently outspent Iovance, with its SG&A expenses peaking at approximately $402 million in 2023, a 23% increase from 2014. In contrast, Iovance's expenses grew more modestly, reaching around $107 million in 2023, marking a significant 104% increase from its 2014 figures. This disparity highlights ACADIA's aggressive investment in administrative and sales functions, potentially reflecting a broader strategy to capture market share. Meanwhile, Iovance's more conservative spending may indicate a focus on lean operations. Understanding these trends provides valuable insights into each company's strategic priorities and financial health.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025